N-Acetylcysteine: An old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura

Transfusion

Volumn 54, Issue 5, 2014, Pages 1205-1207

  George, James N ^a,b   Lõpez, José A ^c   Konkle, Barbara A ^c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLEEDING; DRUG INDICATION; DRUG SAFETY; EDITORIAL; HUMAN; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE;

ACETYLCYSTEINE; FEMALE; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84900409135     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12561     Document Type: Editorial

References (16)

1. Prescott LF, Park J, Ballantyne A, et al. Treatment of paracetamol (acetaminophen) poisoning with N-Acetylcysteine. Lancet 1977; 2: 432-434. (Pubitemid 8167941)
2. Holdiness MR,. Clinical pharmacokinetics of N-Acetylcysteine. Clin Pharmacokinet 1991; 20: 123-134.
3. Horowitz RS, Dart RC, Jarvie DR, et al. Placental transfer of N-Acetylcysteine following human maternal acetaminophen toxicity. J Toxicol Clin Toxicol 1997; 35: 447-452.
4. Manthripragada AD, Zhou EH, Budnitz DS, et al. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States. Parmacoepidemiol Drug Saf 2011; 20: 819-826.
5. Cumberland Pharmaceuticals, Inc. Acetadote (acetylcysteine) injection. Package insert 2013.
6. Zed PJ, Krenzelok EP,. Treatment of acetaminophen overdose. Am J Health Syst Pharm 1999; 56: 1081-1093. (Pubitemid 29259049)
7. Wijeysundera DN, Karkouti K, Rao V, et al. N-Acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery. Crit Care Med 2009; 37: 1929-1934.
8. Nieme TT, Musterhjelm E, Poyhia R, et al. The effect of N-Acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. Blood Coagul Fibrinolysis 2006; 17: 29-34. (Pubitemid 43170751)
9. Knudtsen TT, Thorsen S, Jensen SA, et al. Effect of intravenous N-Acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut 2005; 54: 515-521. (Pubitemid 40395504)
10. Chen J, Reheman A, Gushiken FC, et al. N-Acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121: 593-603.
11. Turner NA, Nolasco LH, Moake JL,. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. Semin Thromb Hemost 2012; 38: 38-46.
12. Li GW, Rambally S, Kamboj J, et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-Acetylcysteine: A case report. Transfusion 2014; 54: 1221-1224.
13. George JN, Vesely SK, Terrell DR, et al. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: A model for clincal research, education and patient care. Haemostaseologie 2013; 33: 105-112.
14. Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013; 60: 1676-1682.
15. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
16. Herper M,. The world's most expensive drugs. Forbes 2010. [cited 2013 Nov 18]. Available from: http://www.forbes.com/2010/02/19/expensive-drugs-cost- business-healthcare-rare-diseases.html.